37 results about "Paenibacillus lactis" patented technology

Exemplary methods and systems for killing or deactivating spores include applying a fluid to a surface containing a spore; and applying direct or indirect plasma to the surface for a period of time. In some embodiments, the fluid includes water. In some embodiments, the spore is Clostridium difficile and in some is Bacillus Anthracis. In some embodiments, the fluid is in the form of a vapor, a fog, a spray, a mist or an aerosol, which may be activated prior to or after applying the fluid to a surface. In some embodiments, peroxynitrite is created in the fluid during the method. Another exemplary embodiment of killing or deactivating a spore includes treating spores with direct plasma or indirect plasma for a period of time and applying an antimicrobial to the spores. In some embodiments, the antimicrobial is an alcohol, a bleach or an alcohol-based sanitizer.

The present invention relates to a method for expressing a target protein on the surface of a microorganism using Bacillus anthracis exosporium protein. More particularly, to an expression vector constructed such that it comprises bclA gene encoding Bacillus anthracis exosporium protein BclA or fragments thereof as a cell surface anchoring motif and the target protein can be expressed on the surface of a cell in a form fused with BclA or a fragment thereof when the gene encoding the target protein is expressed in a host cell, as well as, a method for expressing a target protein on the surface of a microorganism using the vector. The expression vector according to the present invention is capable of effectively expressing a target protein or a peptide on the cell surface using BclA, Bacillus anthracis exosporium protein as a cell surface anchoring motif, and since a target protein can be stably expressed on the cell surface in large amounts by culturing a microorganism transformed with the expression vector, thus making it possible to effectively use for the various purposes of recombinant live vaccines, whole cells absorbents, whole cell bioconversion and the like.

A real-time method employing a portable peptide-containing potentiometric biosensor, can directly detect and / or quantify bacterial spores. Two peptides for specific recognition of B. subtilis and B. anthracis Sterne may be immobilized by a polysiloxane monolayer immobilization (PMI) technique. The sensors translate the biological recognition event into a potential change by detecting, for example, B. subtilis spores in a concentration range of 0.08-7.3×104 CFU / ml. The sensing method exhibited highly selective recognition properties towards Bacillus subtilis spores over other kinds of spores. The selectivity coefficients of the sensors for other kinds of spores are in the range of 0-1.0×10−5. The biosensor method not only has the specificity to distinguish Bacillus subtilis spores in a mixture of B. subtilis and B. thuringiensis (thur.) Kurstaki spores, but also can discriminate between live and dead B. subtilis spores. Furthermore, the sensing method can distinguish a Bacillus subtilis 1A700 from other B. subtilis strain. Assay time may be as low as about 5 minutes for a single test. Rapid identification of B. anthracis Sterne and B. anthracis ΔAmes was also provided.

Regions of Bacillus anthracis protective antigen are provided representing epitopes recognized by antibodies in subjects that have acquired immunity to Bacillus anthracis infection. The recognition of these epitopes correlates with autoimmunity in a subject. Also provided are vaccines that include at least one of these epitopes that when administered to a subject provide improved acquired immunity.

The invention discloses a method and a complete set of reagents for detecting Bacillus anthracis with RPA combined with CRISPR technology. The present invention provides a set of primers for detecting Bacillus anthracis and / or screening virulent strains of Bacillus anthracis, including three sets of primers specific to the chromosomal gene BA_5345 of the virulent strain of Bacillus anthracis, the plasmid virulence genes pagA and capA, Each set of primers is composed of RPA primers and crRNA, and the RPA primers are designed according to the conserved sequence of the target gene, and the crRNA includes an anchor sequence capable of binding to the cas protein and a spacer sequence matching the sequence of the amplification product of the RPA primer. The complete primer set of the present invention has good sensitivity and specificity for detection of clinical simulation samples and soil simulation samples, can effectively distinguish virulent strains of Bacillus anthracis from other bacteria, and provides a rapid detection method for in vitro diagnosis of Bacillus anthracis. Soil environmental screening of Bacillus anthracis in epidemic areas in China is of great significance.

Substrates for detecting microorganisms are provided, wherein the substrate comprises a set of molecular markers linked, optionally with linker molecules or moieties, to a di-, or tripeptide consisting of amino acids X1 and X2, or X1, X2 and X3, in which one of them, for example, X1, is a D-amino acid and the others, for example, X2 and X3, may be any D- or L-amino acid. The substrate preferably is used for the detection of Bacillus anthracis. Also provided are substrates for detecting Pseudomonas aeruginosa, wherein the substrate comprises a set of molecular markers linked, optionally with linker molecules or moieties to a tri-, tetra-, or pentapeptide consisting of glycine amino acids. The invention further comprises methods for detecting microorganisms, specifically B. anthracis and P. aeruginosa, with the substrates of the invention and use of the substrate(s) in such a method.

The invention relates to a humanized nucleic acid construct from Bacillus anthracis protective antigen (PA) gene and method of modifying the gene. The humanized gene, and method of producing it, improves the structural fidelity of expressed protein product, when produced in mammalian host cells, to native, bacterially produced protein. The construct is useful in nucleic acid based vaccine formulations against B. anthracis.

This disclosure generally relates to therapeutic antibodies for treating Bacillus anthracis (B. anthracis) infection, to specific variants thereof, pharmaceutical composition comprising them and to methods for their use.